标题
Gemtuzumab ozogamicin in acute myeloid leukemia
作者
关键词
-
出版物
LEUKEMIA
Volume 31, Issue 9, Pages 1855-1868
出版商
Springer Nature
发表日期
2017-06-13
DOI
10.1038/leu.2017.187
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
- (2017) M Wattad et al. LEUKEMIA
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab
- (2016) Yasmin Abaza et al. BLOOD
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
- (2016) U. Reusch et al. CLINICAL CANCER RESEARCH
- Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
- (2016) Magali Guffroy et al. CLINICAL CANCER RESEARCH
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2016) Jessica A. Pollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry
- (2016) Jametta S. Magwood-Golston et al. LEUKEMIA RESEARCH
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
- (2016) George S. Laszlo et al. Oncotarget
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Novel insights on the DNA interaction of calicheamicin γ1I
- (2015) Claudia Sissi et al. BIOPOLYMERS
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
- (2015) K. Tarlock et al. CLINICAL CANCER RESEARCH
- Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia
- (2015) M. Malik et al. HUMAN MOLECULAR GENETICS
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
- (2015) Alan K Burnett et al. LANCET ONCOLOGY
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Human-specific derived alleles ofCD33and other genes protect against postreproductive cognitive decline
- (2015) Flavio Schwarz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
- (2014) M.-A. Hospital et al. BLOOD
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Gemtuzumab ozogamicin in acute myeloid leukemia revisited
- (2014) Felicitas Thol et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility
- (2014) T. Raj et al. HUMAN MOLECULAR GENETICS
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
- (2014) Alan S. Gamis et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
- (2014) William E. Pierceall et al. LEUKEMIA RESEARCH
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
- (2013) Carol O'Hear et al. CANCER
- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy
- (2013) L. Mortland et al. CLINICAL CANCER RESEARCH
- Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
- (2013) Roland Walter Frontiers in Bioscience-Landmark
- Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
- (2013) Akihiro Takeshita INTERNATIONAL JOURNAL OF HEMATOLOGY
- Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
- (2013) Martin S. Tallman et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
- (2013) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing
- (2013) M. Malik et al. JOURNAL OF NEUROSCIENCE
- CD33 in Alzheimer's Disease
- (2013) Teng Jiang et al. MOLECULAR NEUROBIOLOGY
- CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
- (2013) Elizabeth M Bradshaw et al. NATURE NEUROSCIENCE
- Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
- (2013) Ana Griciuc et al. NEURON
- AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
- (2013) David B. Rosen et al. PLoS One
- Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
- (2012) H. Hasle et al. BLOOD
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
- (2012) J. A. Pollard et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells
- (2012) Takahiro Yamauchi et al. CANCER SCIENCE
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
- (2012) G. Borthakur et al. HAEMATOLOGICA
- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
- (2012) M. A. Sekeres et al. HAEMATOLOGICA
- Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
- (2012) Tetsuya Tanimoto et al. INVESTIGATIONAL NEW DRUGS
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
- (2011) U. Brunnberg et al. ANNALS OF ONCOLOGY
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
- (2011) H. F. Fernandez et al. BLOOD
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
- (2011) R.-O. Casasnovas et al. BLOOD
- Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia
- (2011) Marie-Luise Hütter et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells
- (2011) A. B. Perez-Oliva et al. GLYCOBIOLOGY
- High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
- (2011) M. S. De Propris et al. HAEMATOLOGICA
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia
- (2011) F. Bouquet et al. JOURNAL OF CELL SCIENCE
- Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
- (2011) Eva Jager et al. PLoS One
- Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)
- (2010) Iris Middeldorf et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
- (2010) B. Lowenberg et al. BLOOD
- Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine
- (2010) Thomas Prebet et al. CANCER
- Circulating CD33 and its clinical value in acute leukemia
- (2010) Adam Abdool et al. EXPERIMENTAL HEMATOLOGY
- Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
- (2010) Massimo Breccia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin
- (2008) M. B. Maniecki et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search